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Bone biology in multiple myeloma
The maintenance of skeletal integrity requires a strict ba-
lance between the anabolic and resorptive actions of oste-
oblasts and osteoclasts, respectively. Osteoclasts are large
multinucleated cells derived from the monocyte / macro-
phage lineage that are responsible for the resorption of
bone. Its recruitment, activity, and apoptosis are under
the modulation of a series of hormones and cytokines
and under the control of the cells of osteoblastic lineage.
Osteoclast differentiation requires cell-cell contact be-
tween osteoblastic / stromal cells and cells of the hemato-
poietic lineage. Recently, proteins involved in the cell-
-cell interaction have been identified. RANKL (receptor
activator of nuclear factor NF-κβ ligand) [which is identi-
cal to TRANCE (TNF – related activation – induced cy-
tokine) and ODF (osteoclast differentiation factor) /
OPGL (osteoprotegerin ligand)] was identified as the li-
gand [1]. RANKL is a member of the TNF ligand family
and is expressed by osteoblastic / stromal cells. RANKL
activates its receptor RANK, which is expressed on oste-
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Bisphosphonates are potent inhibitors of myeloma – induced osteoclast – mediated bone resorption. On the basis of the pu-
blished studies one may conclude that long – term oral clodronate administration (1600-2400 mg daily) as an adjunct to che-
motherapy in patients with multiple myeloma with osteolysis is an efficient approach in prevention of hypercalcaemia and ame-
lioration of skeletal morbidity. Intravenous clodronate and intravenous pamidronate in a single dose of 1500 mg and 90 mg,
respectively is efficient in the treatment of hypercalcaemia and may be recommended in patients with normal renal function.
Monthly intravenous pamidronate administration (60-90 mg) as an adjunct to chemotherapy in patients with multiple myelo-
ma with osteolysis reduces bone pain and is efficient in the prevention and treatment of hypercalcaemia and reduces skeletal
morbidity. Occurrence or worsening of anaemia during long – term pamidronate treatment deserves attention and further stu-
dy. Caution must be exercised before concluding that clodronate and pamidronate improves survival in multiple myeloma.
The role of bisphosphonates in the treatment of myeloma induced hypercalcaemia is already established but despite their in-
creasing use in oncological practice the questions regarding the optimal selection of patients and the duration of treatment of
myelomatous bone disease remain unanswered.
Choroba koÊci i bisfosfoniany w szpiczaku plazmocytowym
Bisfosfoniany hamujà resorpcj´ kostnà, zwiàzanà ze szpiczakowà aktywacjà uk∏adu osteoklastów. Opublikowane badania
wskazujà, ˝e d∏ugotrwa∏e stosowanie klodronianu doustnie (w dawkach 1600-2400 mg dziennie), jako leczenia wspomaga-
jàcego chemioterapi´ u chorych na szpiczaka plazmocytowego z osteolizà, jest post´powaniem zmniejszajàcym niebezpieczeƒ-
stwo wyst´powania hiperkalcemii i ∏agodzàcym chorob´ koÊci. Podobnie, jak pamidronian w dawce do˝ylnej 90 mg, do˝ylne
stosowanie klodronianu w jednorazowej dawce 1500 mg jest skuteczne w leczeniu hiperkalcemii i mo˝e byç zalecane u cho-
rych z prawid∏owà czynnoÊcià nerek. D∏ugotrwa∏e stosowanie comiesi´cznych infuzji do˝ylnych pamidronianu (w dawkach 60-
-90 mg), jako leczenia wspomagajàcego chemioterapi´ u chorych na szpiczaka plazmocytowego z osteolizà, zmniejsza niebez-
pieczeƒstwo wyst´powania hiperkalcemii i powik∏aƒ kostnych, a w pierwszych miesiàcach leczenia zmniejsza tak˝e bóle
kostne, ale cz´stsze wyst´powanie lub pog∏´bianie si´ niedokrwistoÊci wymaga uwagi i dalszych badaƒ. Wp∏yw klodronianu i pa-
midronianu na czas prze˝ycia chorych na szpiczaka jest wàtpliwy. W chwili obecnej stosowanie bisfosfonianów w leczeniu hi-
perkalcemii szpiczakowej jest uzasadnione, natomiast nie ustalono optymalnych wskazaƒ do ich stosowania w zapobieganiu
i leczeniu szpiczakowych powik∏aƒ kostnych.
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oclasts and osteoclast progenitor cells, to induce osteoc-
last differentiation and function. A decoy receptor, OPG
/ OCIF (osteoclastogenesis inhibitory factor), has also
been identified. OPG (osteoprotegerin) is a secreted
member of the TNF receptor family. OPG binds to
RANKL, thus inhibiting osteoclast differentiation or func-
tion. Cells of lymphatic system also express RANK,
RANKL, and OPG.
A number of studies have demonstrated that bone re-
sorption is increased in patients with multiple myeloma [2,
3, 4, 5]. Increased resorption has also been detected in
patients defined as having early myeloma [2], or with a low
tumour infiltration of the bone marrow [4], suggesting
that increased resorption is an early event in the disease
process. The increased bone resorption observed in pa-
tients with multiple myeloma is associated with tumour
infiltration and correlates with tumour burden [4, 6]. My-
eloma cells are found closely associated with bone surfaces
actively undergoing bone resorption, suggesting that tumo-
ur cells stimulate the resorption process directly. Apart
from that, myeloma cells can secrete, or stimulate other lo-
cal cells to secrete, a series of bone – resorbing cytokines
such as IL-6, IL-1β, TNFβ, MIP1a, PTH-related protein
which induce osteoclasts to resorbe bone. RANKL /
TRANCE, a cytokine normally responsible for the genera-
tion and survival of osteoclasts, mediates myeloma- asso-
ciated bone destruction. RANKL / TRANCE expression is
stimulated by ligands which signal through G – proteins,
STATs, TNF and TGF-β receptors. As mentioned previo-
usly malignant plasma cells produce a number of osteoc-
last activating factors that stimulate stromal cell expression
of RANKL / TRANCE by triggering these signaling path-
ways. RANKL / TRANCE, in turn, binds to its receptor on
myeloid precursor to foster the development of osteoc-
lasts. Pearse et al. [7] identified TRANCE as the com-
mon mediator of myeloma – induced osteolysis. They de-
monstrated that bone marrow biopsies from patients with
myeloma – induced osteolysis display overexpression of
TRANCE mRNA by bone stroma and they also found
that inhibitors of TRANCE signaling inhibit myeloma – in-
duced osteoclastogenesis, whereas inhibitors of any single
osteoclast activating factor give variable results.
Bone destruction caused by aberrant production and
activation of osteoclasts, results in significant morbidity
for over 80% of patients with multiple myeloma [8]. Loca-
lized osteolysis can lead to fractures, pain and hypercalca-
emia.
Mechanisms of action of bisphosphonates
Bisphosphonates are analogs of endogenous pyropho-
sphate in which a carbon atom replaces the central atom
of oxygen (Fig 1). This carbon substitution makes these
compounds resistant to hydrolysis (to endogenous
phosphatases). Binding to the mineral appears to be due
to the P-C-P structure, while the antiresorptive activity
is influenced both by the P-C-P part and by the structure
of the side chains. Bisphosphonates have a high affinity
for bone mineral and will selectively target to bone surfa-
ces. They preferentially bind to bones that have high rates
of bone turnover (ie, undergoing increased bone resorp-
tion or formation). Thus these agents are concentrated at
the exposed bone surface that undergoes active remode-
ling.The binding of these substances is usually reversible
at sites where the bone surface is accessible to the extra-
cellular fluid. However, it is irreversible at sites which
become buried by new bone formation, until the bone
with the bisphosphonate is destroyed again during mode-
ling or remodeling.
The following bisphosphonates have been investiga-
ted in animals and humans with respect to their effect
on bone: alendronate, clodronate, EB-1053, etidronate,
ibandronate, incadronate, minodronate, neridronate, ol-
padronate, pamidronate, risedronate, tiludronate, zole-
dronate. The potency of different bisphosphonates on
bone resorption varies from 1 for etidronate to approxi-
mately 10.000 for zoledronate in the rat, about 10 or mo-
re times less in humans (Fig. 2).
The inhibition of bone resorption occurs as a result of
the effect of these drugs on osteoclast, both directly and in-
directly. Bisphosphonates were first shown to reduce oste-
Fig.1. Chemical structure of bisphosphonates
Fig.2. Inhibitory activity of bone resorption of various bisphosphonates in
vitro in mouse calvariae and in vivo in the thyroparathyroidectomized rat
153
oclast development from their precursors, as well as inhi-
biting movement of osteoclasts to the bone surface, where
they would normally resorb bone. Recent studies have
shown that these compounds maybe internalised by oste-
oclasts and interfere with specific biochemical pathways
that ultimately lead to osteoclast apoptosis. The nature
of the specific molecular targets is only now becoming
clear. It was found that nitrogen containing bisphosphona-
tes (risedronate, zoledronate, ibandronate, alendronate,
pamidronate) can inhibit the mevalonate pathway, by inhi-
biting farnesyl pyrophosphate synthase. This leads to a de-
crease of the formation of isoprenoid lipids such as farne-
syl – and geranyl – geranyl – pyrophosphates. These are re-
quired for the post – translational prenylation of proteins,
including the GTP – binding proteins Ras, Rho, Rac, and
Rab. These proteins are important for many cell func-
tions, including cytoskeletal assembly and intracellular si-
gnaling. Therefore, disruption of their activity will induce
a series of changes leading to decreased activity, probably
the main effect, and to earlier apoptosis in several cell ty-
pes, including osteoclasts. In osteoclasts the lack of gera-
nylgeranylpyrophosphate is probably responsible for the
effects [9, 10, 11]. It was also shown that some non – nitro-
gen – containing bisphosphonates such as etidronate, clo-
dronate, and tiludronate, can be incorporated into the
phosphate chain of ATP – containing compounds so that
they become nonhydrolyzable. The new P-C-P containing
ATP analogs inhibit cell function and may lead to apopto-
sis and cell death [10, 12, 13].
Several in vivo animal and in vitro human studies sup-
ported the possible role of bisphosphonates as antimyelo-
ma agents. By inhibiting bone resorption bisphosphona-
tes may alter the local factors that may be important in
the growth and survival of the tumour cells. A reduction in
the production of the cytokine IL – 6 from bone marrow
stromal cells exposed to bisphosphonates has been found
(Savage et al. 1996 – Congress publication). The osteoclast
itself is a potent producer of this same cytokine. Il-6 not on-
ly enhances bone resorption but also is an important
growth factor for myeloma. As such, reducing the availabi-
lity of this cytokine in the bone microenvironment by expo-
sure to bisphosphonates may not only inhibit bone resorp-
tion but may inhibit tumour growth as well.
Recent studies have suggested that pamidronate, inca-
dronate and zoledronate can inhibit myeloma cell prolife-
ration and induce tumour cell apoptosis in vitro [14, 15].
This effect has also been observed in primary myeloma
cells isolated from patients with multiple myeloma [14].
Furthermore, bisphosphonates appear to be able to cause
apoptosis of human myeloma cells by inhibiting enzymes of
the mevalonate pathway, suggesting a similar molecular
mechanism of action to that seen in osteoclasts [16].
Yaccoby et al. [17] have shown a reduction in lytic
bone lesions and tumor burden in severe combined im-
munodeficiency mice that were implanted with fresh hu-
man myeloma bone marrow and fetal bone and were tre-
ated with pamidronate. However, treatment with iban-
dronate, which is more potent than pamidronate, in
a murine model of myeloma showed only a reduction in
lytic bone disease, without an impact on tumour burden
[18]. Croucher et al. have investigated the effect of iban-
dronate in the 5T2 murine model of myeloma in which
the bisphosphonate was administered once the myeloma
disease had established. Treatment with ibandronate had
no effect on tumour burden or tumour cell apoptosis. Ta-
ken together these murine studies suggest that bispho-
sphonates are able to modulate the development of the
bone disease but have little effect on the tumour itself.
However, clinically in a study of two patients with establi-
shed myeloma, pamidronate was shown to significantly
decrease the proportion of bone marrow plasma cells
and concentration of serum monoclonal protein [19].
Bisphosphonate treatment in multiple myeloma
Bisphosphonates have become useful in the treatment
of diseases characterised by increased bone resorption.
The following bisphosphonates are commercially available
in some countries for use in human bone disease: etidro-
nate, clodronate, pamidronate, alendronate, ibandronate,
risedronate, tiludronate. A number of studies have inve-
stigated the effect of etidronate, clodronate and pami-
dronate on the development of osteolytic bone disease in
patients with multiple myeloma [20-33].
Oral etidronate has been found to be ineffective in
patients with multiple myeloma [20].
The Finnish Myeloma Trial with 350 patients was
multicenter study where all patients received melphalan –
prednisolone and were randomized to receive oral clodro-
nate 2400 mg daily or placebo for 24 months. The propor-
tion of patients with progression of osteolytic bone le-
sions was 24% in the placebo group and 12% in the clo-
dronate group (p=0.026). Progression of vertebral
factures was lower in the clodronate group but the diffe-
rence was not significant (30% vs 40%) [29].
In the Mc Closkey et al. study [31] carried out within
the framework of the VI th MRC Multiple Myeloma Trial
536 patients with recently diagnosed multiple myeloma
were randomized to receive either clodronate 1600 mg
daily or placebo in addition to polychemotherapy
(ABCM, ABCMP). The minimum follow-up for all pa-
tients was 1.3 years. Treatment with clodronate decre-
ased the incidence of severe hypercalcaemia (5% vs 10%,
p=0.06). The occurrence of pathological fractures at both
non-vertebral (6.8% vs 13.2%) and vertebral (38% vs
55%) sites was significantly reduced with a significant
prevention of height loss. The reduction in the incidence
of non-vertebral and vertebral factures was observed wi-
thin the first year of treatment and persisted throughout
the duration of exposure. The median overall survival
from the entry into the study was 2.9 years for patients re-
ceiving clodronate and 2.8 years for patients receiving
placebo.
In the Kraj et al.' trial [26] a comparative study on
clodronate efficacy in prevention of new osteolytic foci oc-
currence, prevention and treatment of hypercalcaemia
and hypercalciuria as well as bone pain has been carried
out in 61 multiple myeloma patients with osteolysis. In all
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patients chemotherapy according to VMBCP or
VMCP/VBAP regimens was administered. Thirty one
patients received clodronate (Bonefos; Leiras) per os 2.4
g/24hrs. Median treatment duration amounted 17 months
and in 14 patients treatment duration exceeded 24 mon-
ths. Assessment of patients' survival time was further con-
ducted during the next 5 years after discontinuation of
clodronate treatment. Bone pain reduction was not si-
gnificantly greater and incidence of hypercalcaemic episo-
des was lower in the group of patients treated with clodro-
nate compared to the control group (8 vs 14, p<0.05).
After 24 months a further osteolysis progression occurred
in 43% of clodronate treated patients and in 60% of tho-
se in the control. The number of new vertebral fractures
observed during the first year of treatment in the con-
trol group and in the clodronate group were similar – 79
versus 72/100 patient – year, respectively. Proportions of
patients experiencing new vertebral factures after the se-
cond year of the study was insignificantly lower in the
clodronate group than in the control (37% versus 46%,
p=0.1) while the corresponding ratios of new vertebral
fractures /100 patients – year were 28 and 41 (p=0.08), re-
spectively. Patients' survival time did not differ between
two compared groups. Median survival time since the
diagnosis of multiple myeloma in the clodronate treated
patients is 60 months while in the control group – 64
months (p=0.9).
The outcomes of clodronate efficacy in multiple my-
eloma achieved in Kraj et al.' study [26] are not so co-
nvincing as those obtained in Finnish and British trials- so
far the largest investigations dealing with oral clodronate
effectiveness in myelomatosis [29, 31]. This inconsistency
is perhaps connected with the fact that clodronate in afo-
re-mentioned studies was administered in patients with
recently diagnosed multiple myeloma both with and wi-
thout osteolysis and presenting also early stages of mali-
gnancy.
In one open controlled prospective study of paren-
terally administered clodronate, at a dose of 600-1000
mg /4-6 weeks, in addition to cytostatic therapy survival
for multiple myeloma patients on clodronate prophyla-
xis was longer than for those who did not receive clodro-
nate prophylaxis [32]. Another study of 1600 mg/day
oral clodronate showed less progression in bone and
less pain in the clodronate group [25].
Early studies documented a reduction of biochemical
markers of bone resorption and bone pain in patients
with myeloma which could be attributed to the effects of
pamidronate treatment [23, 30, 33].
In the Berenson's et al. [21] study 392 stage III mul-
tiple myeloma patients with osteolysis were randomized to
obtain either pamidronate at a dose of 90 mg or placebo
both in 4 – hour intravenous infusion administered every
four weeks and combined with anti – tumour chemothera-
py. The outcomes of a such treatment presented in 1996
after administration of 9 cycles showed in the pamidrona-
te arm a remarkable decrease in proportion of patients
experiencing bone fractures and requiring orthopedic –
surgical management, radiotherapy (24% v 42%) as well
as a significant decrease in proportion of those with episo-
des of hypercalcaemia during first three months of treat-
ment (1% v 5%). Pamidronate treatment was accompa-
nied by significant bone pain diminishing, decrease in an-
tianalgesic drugs consumption and improvement of the
patients' quality of life. In 150 patients the treatment with
pamidronate was continued and 41% of them obtained 21
cycles of therapy. After administration of 21 treatment
cycles in the pamidronate – treated group there was obse-
rved a decrease both in the proportion of patients expe-
riencing various bone complications and in number of
bone complications. Among all 392 patients there was
no difference in overall survival between the pamidro-
nate and placebo groups while the median survival of pa-
tients included into the study during second – line or gre-
ater chemotherapy programs was 21 months for patients
receiving pamidronate and 14 months for patients rece-
iving placebo [22].
In the Kraj et al.' study [27, 28] since October 1995
the efficacy of pamidronate, has been evaluated in multi-
ple myeloma patients all receiving anti-myeloma chemo-
therapy acc. to VMCP/VBAP alternating regimen. Forty
– six patients with stage III myeloma and osteolytic lesions
were randomized to receive either pamidronate (Aredia;
Novartis) 60 mg i.v. in 4- hour infusion monthly (n=23) or
chemotherapy alone (control group n=23). During the
pamidronate treatment there was observed bone pain re-
duction and improvement of bone turnover indices. Ho-
wever, only in the first 8 months of treatment the reduc-
tion of clinical symptoms related to bone destruction was
greater in patients treated with pamidronate in compari-
son to control group receiving only chemotherapy. The
pamidronate administration was associated with a not si-
gnificant decrease in the proportion of patients with hy-
percalcaemia but the mean serum calcium concentration
remained in the normal limits during the whole period of
study. At skeletal X-ray examination performed after 6,
12, 18 and 21 cycles of pamidronate and by comparing
each consecutive imaging with previous one the progres-
sion of osteolysis was found respectively in 67%, 39%,
27% and 33% of patients. In the control group corre-
sponding figures were: 79%, 70%, 30% and 25%. The
mean number of skeletal events (pathologic fractures,
radiation or surgery to bone and spinal cord compres-
sion) per year was lower in the pamidronate group (1.82)
than in the control patients (2.72), p>0.013. The propor-
tion of patients who had developed skeletal events (exclu-
ding vertebral fractures) was lower in the pamidronate
group – 34% v 52% (p>0.023). The proportion of pa-
tients with pathologic vertebral fractures was similar 69%
v 70%, respectively but the number of vertebral fractures
was lower in the pamidronate group, 45 v 64 (1.4 v 2.3 per
patient per year; p>0.04). Decreases of blood haemo-
globin level occurred more frequently in pamidronate
patients than in the controls (72% v 41%, respectively)
and mostly were accompanied by progression of prolifera-
tion. Survival was not different between the pamidronate
– treated group and control patients (20 v 19 months sin-
ce randomisation, p>0.65 and 62 v 50 months since mul-
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tiple myeloma diagnosis, p>0.45). Thirteen (=56%) pa-
tients in the pamidronate group died, as did 12 (=52%) in
the control group [23]. Continuation of the study up to 34
cycles of pamidronate have shown that along with exten-
sion of treatment the effect of pamidronate on skeletal
morbidity becomes less pronounced [34].
A special attention should be paid to one patient
(Kraj et al. [35]) in whom the treatment composed of ra-
diotherapy combined with pamidronate administration
resulted in reconstruction of myelomatous vertebral le-
sions. Such diminishing of osteolytic lesions with simulta-
neous improvement in bone structure calcification is an
extremely rare event in multiple myeloma even in pa-
tients in whom their tumour proliferation process was
inhibited in result of successful chemotherapy. In this pa-
tient, aged 38, engineer, trade specialist, having multiple
myeloma with monoclonal protein IgGκ and BBJκ, 15%
rate of bone marrow plasma cells and osteolysis there
was observed the following course of malignancy, dia-
gnosing and treatment. In 1992 a X-ray survey revealed
osteolytic lesion of C-2 vertebra. In 1995, radiologic ske-
letal examination disclosed – in addition to osteolytic ver-
tebral destruction of C-2 – the osteolytic foci in C-5 and
C-6 vertebras; magnetic resonance imaging showed alte-
rations in spinal cervical region excluding however spinal
cord lesion. The same year too, the patient apart from
continuing chemotherapy according to VMCP/VBAP
program was subjected radiation to cervical vertebral re-
gion, and beginning from 1996 he started the treatment
with pamidronate (Aredia) systematically, every month,
administered in dose of 60 mg in intravenous infusions.
Till February 2000, he received 36 cycles of such treat-
ment. The treatment resulted in bone reconstruction of
vertebra C-2 and stabilisation of osteolysis in other bones.
The patient continues to perform his full-time job and
does not require analgesic treatment. This case was pre-
sented at XVII Congress of the Polish Society of Haema-
tology and Blood Transfusion in ¸ódê, June 1999 [35].
The encouraging data on early progression adapted
use of bisphosphonates in myeloma were presented at
VII International Multiple Myeloma Workshop in Stoc-
kholm, Sweden, September 1999 by R. Bartl [36] from
the University Hospital Grosshadern, Munich, Germa-
ny. One hundred sixty myeloma patients in stage I and wi-
thout osteolytic lesions were treated with aminobispho-
sphonates from time of diagnosis. Pamidronate (60-120
mg) or ibandronate (2-6 mg) were used intravenously
and the dosages and infusion intervals (from 1 to 3 mon-
ths) depending on the intrinsic malignancy of the disease
(spectrum from smouldering to rapidly progressive va-
riants). In this non – randomized study he could demon-
strate a marked reduction of skeletal events in the first 3
years and especially a reduction of tumour growth (shown
in MRI of the skeleton, bone biopsy and PCLI) and
a decline of the M – protein levels in the first year of tre-
atment (no concomitant chemotherapy!).
Oral pamidronate (300 mg/24h) was compared with
placebo in 300 newly diagnosed myeloma patients who
were also receiving intermittent oral melphalan and pred-
nisone [11]; pamidronate had no effect on skeletal – rela-
ted morbidity or survival.
Early clinical studies used bisphosphonates in the
treatment of hypercalcaemia of malignancy [37, 38]. In
the study of Kraj et al. [26] in 11 patients with hypercalca-
emia clodronate was applied i.v. 0.3g/24hrs in 4-hour infu-
sion for 5 days and in 3 patients-1.5g/24hrs for 1 day. In-
travenous administration of clodronate in all cases led
to normalisation of serum calcium concentration during 2-
-4 days. In this study, similary to the O`Rourke et al. [38]
experience, intravenous clodronate at dose of 1500mg
was efficient in the treatment of hypercalcaemia and a sin-
gle-day 1500 mg was as efficient as a 5-day treatment
with 300 mg daily. Another study has shown the efficacy
of intravenous pamidronate in reversing hypercalcaemia
in cancer patients and revealed the drug dose of 90mg
as optimal [37].
A randomized trial has shown the superiority of pa-
midronate over clodronate in patients with tumour-in-
duced hypercalcaemia essentially about the duration of
normocalcaemia, because the median duration of action
of clodronate was 14 days compared with 28 days for pa-
midronate [39].
Zoledronate is a heterocyclic imidazole containing
third generation bisphosphonate (Fig.1), which is so far
the most potent bisphosphonate evaluated in humans. It
is 100 times more potent than pamidronate in inhibiting
1.25(OH)2D induced release of calcium from mouse ca-
lvaria in vitro. In the in vivo animal model of calcitriol in-
duced hypercalcaemia in thyroparathyroidectomized rats,
zoledronate is 850 times more active than pamidronate
and more than 4 orders of magnitude more potent than
clodronate (Fig.2) [40]. Of all bisphosphonates clinically
evaluated, zoledronate has the largest therapeutic ratio
between the desired inhibition of bone resorption and
the unwanted inhibition of bone mineralization.
Zoledronate is under development but not yet ap-
proved for marketing in any country. Body et al. (41)
conducted an open-label, dose-finding, single-dose phase
I study in tumour-induced hypercalcaemia in 33 patients.
The primary objective was determine, with a dose escala-
tion schedule, two nontoxic dose levels of zoledronate
able to induce normocalcaemia in at least 80% of pa-
tients with hipercalcaemia of malignancy after rehydra-
tion. The two effective dose levels were 0.02 mg/kg and
0.04  mg/kg (i.e. 1.2 mg and 2.4 mg for a 60-kg individual,
respectively). At the latter dose, the first day of normocal-
caemia was day 2 or 3, and normocalcaemia was often
maintained throughout the trial – 32 to 39 days.
Zoledronate is, now being compared with pamidro-
nate in a large randomized double-blind trial for patients
with multiple myeloma related bone lesions.
Prof. Maria Kraj
Department of Haematology,
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